| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 13,706.9 | 11,200.43 | 22.38 | ||
| Gross Profit (Loss) | 4,207.01 | 3,744.26 | 12.36 | ||
| Operational Profit (Loss) | 2,618.98 | 2,356.26 | 11.15 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 2,401.47 | 2,315.29 | 3.72 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 2,389.07 | 2,331.16 | 2.48 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 7,901.72 | 7,175.14 | 10.13 | ||
| Profit (Loss) per Share | 6.86 | 6.62 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Revenues for FY 2025 grew by 22.38% reaching SAR 13,706.90 million, compared to SAR 11,200.43 million in FY 2024, representing an increase of SAR 2,506.47 million. This growth was primarily driven by both the hospitals and pharmacies segments, supported by higher patient volumes and higher occupancy rates. As part of its ongoing growth strategy, the Group launched several new hospitals across key regions. In 2024, operations commenced at Al-Fayhaa Hospital (Al-Fayhaa District, Jeddah), Shamal Al Riyadh Hospital (Al-Sahafa District, Riyadh), and the Women’s Health Hospital (Rahmaniyah District, Riyadh). The expansion continued in 2025 with the commencement of operations at Al-Hamra Hospital (Al-Hamra District, Riyadh), Al-Kharj Hospital (Al-Jawhara District, Al-Kharj), and Al Muhammadiyah Hospital (Al Muhammadiyah District, Jeddah). Newly commissioned hospitals are currently in the ramp-up phase, and revenue contribution is expected to increase progressively as they move toward optimal utilization. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | EBITDA increased by 17.86% reaching SAR 3,506.95 million (FY 2024: SAR 2,975.43 million). EBITDA margin reached 25.59%. Net profit increased by 3.72% reaching SAR 2,401.47 million (FY 2024: SAR 2,315.29 million). This increase was primarily driven by higher revenues, partially offset by fixed operating costs associated with the newly launched hospitals that are still in their ramp-up stages and are expected to progressively reach optimal operational capacity. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | na |
| Reclassification of Comparison Items | na |
| Additional Information | na |
| Attached Documents | Attached Documents |
